- Home
- PAC vs INCY Comparison
PAC vs INCY Comparison
Compare PAC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAC
- INCY
- Stock Information
- Founded
- PAC 1998
- INCY 1991
- Country
- PAC Mexico
- INCY United States
- Employees
- PAC N/A
- INCY N/A
- Industry
- PAC Aerospace
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- PAC Consumer Discretionary
- INCY Health Care
- Exchange
- PAC Nasdaq
- INCY Nasdaq
- Market Cap
- PAC 11.7B
- INCY 17.0B
- IPO Year
- PAC 2006
- INCY 1993
- Fundamental
- Price
- PAC $222.25
- INCY $105.55
- Analyst Decision
- PAC Buy
- INCY Buy
- Analyst Count
- PAC 5
- INCY 19
- Target Price
- PAC $210.00
- INCY $89.19
- AVG Volume (30 Days)
- PAC 81.7K
- INCY 2.8M
- Earning Date
- PAC 10-20-2025
- INCY 10-28-2025
- Dividend Yield
- PAC 5.08%
- INCY N/A
- EPS Growth
- PAC 13.32
- INCY 3878.02
- EPS
- PAC 1.07
- INCY 5.90
- Revenue
- PAC $1,870,491,921.00
- INCY $4,813,105,000.00
- Revenue This Year
- PAC $58.23
- INCY $19.33
- Revenue Next Year
- PAC $7.61
- INCY $10.47
- P/E Ratio
- PAC $20.69
- INCY $17.64
- Revenue Growth
- PAC 35.46
- INCY 18.09
- 52 Week Low
- PAC $168.62
- INCY $53.56
- 52 Week High
- PAC $259.33
- INCY $109.28
- Technical
- Relative Strength Index (RSI)
- PAC 53.29
- INCY 68.24
- Support Level
- PAC $213.14
- INCY $91.16
- Resistance Level
- PAC $221.58
- INCY $109.28
- Average True Range (ATR)
- PAC 5.67
- INCY 4.59
- MACD
- PAC 1.62
- INCY 0.49
- Stochastic Oscillator
- PAC 90.99
- INCY 80.28
About PAC Grupo Aeroportuario Del Pacifico
Grupo Aeroportuario del Pacifico SAB de CV is engaged in the construction, development, and operation of airports in Mexico. The company's segment includes Guadalajara; Tijuana; Puerto Vallarta; San Jose del Cabo; Montego Bay; Hermosillo; Guanajuato and Other Airports. It generates maximum revenue from the Guadalajara segment.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.